A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients With Macular Edema Secondary to Central Retinal or Hemiretinal Vein Occlusion
This is a Phase III, multicenter, randomized, double-masked, active comparator-controlled, parallel-group study evaluating the efficacy, safety, and pharmacokinetics of faricimab administered by intravitreal (IVT) injection at 4-week intervals until Week 24, followed by a double-masked period of study without active control to evaluate faricimab administered according to a personalized treatment interval (PTI) dosing regimen in patients with macular edema due to central retinal vein occlusion (CRVO) or hemiretinal vein occlusion (HRVO).
Inclusion Criteria:
Exclusion Criteria:
Ocular Exclusion Criteria for Study Eye:
Ocular Exclusion Criteria for Both Eyes:
Edina, Minnesota 55435, United States
CABA, C1017AAO, Argentina
Capital Federal, C1015ABO, Argentina
Capital Federal, C1120AAN, Argentina
Capital Federal, C1199ABC, Argentina
Ciudad Autonoma Buenos Aires, C1061AAE, Argentina
Vienna, 1090, Austria
Düsseldorf-Oberkassel, 40549, Germany
Rome, Lazio 00198, Italy
Hokkaido, 078-8510, Japan
Gda?sk, 80-402, Poland
Gda?sk, 80-809, Poland
Krakow, 31-501, Poland
Na??czów, 24-140, Poland
Coimbra, 3000-075, Portugal
Cheboksary, Mariy-El Republic 428000, Russia
Moscow, Moscow Oblast 119435, Russia
Saint Petersburg, Sankt-Peterburg 197022, Russia
San Cugat Del Valles, Barcelona 08195, Spain
Liverpool, L7 8YE, United Kingdom